127 related articles for article (PubMed ID: 3054672)
1. Diffuse well-differentiated lymphocytic lymphoma: chemotherapy with BCNU, cyclophosphamide, vincristine, melphalan and prednisone.
Case DC; Boyd M; Hayes DM; Dorsk BM
Oncology; 1988; 45(6):417-20. PubMed ID: 3054672
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy with the M-2 protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for chronic lymphocytic leukemia (stages III and IV).
Case DC; Porensky RS; Fanning JP
Oncology; 1985; 42(6):350-3. PubMed ID: 4069549
[TBL] [Abstract][Full Text] [Related]
3. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
4. A new combination chemotherapy for advanced chronic lymphocytic leukemia (vincristine, cyclophosphamide, melphalan, peptichemio, and prednisone protocol).
Ferrara F; Del Vecchio L; Mele G; Rametta V; Ronconi F; Montuori R
Cancer; 1989 Aug; 64(4):789-92. PubMed ID: 2743271
[TBL] [Abstract][Full Text] [Related]
5. Comparison of M-2 protocol with COP in patients with nodular lymphoma.
Case DC
Oncology; 1984; 41(3):159-63. PubMed ID: 6547220
[TBL] [Abstract][Full Text] [Related]
6. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
[TBL] [Abstract][Full Text] [Related]
7. Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate.
Levitt MJ; Gharibo M; Strair R; Schaar D; Rubin A; Bertino JR
J Chemother; 2009 Aug; 21(4):434-8. PubMed ID: 19622463
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone).
Kempin S; Lee BJ; Thaler HT; Koziner B; Hecht S; Gee T; Arlin Z; Little C; Straus D; Reich L; Phillips E; Al-Mondhiry H; Dowling M; Mayer K; Clarkson B
Blood; 1982 Nov; 60(5):1110-21. PubMed ID: 6751436
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
[TBL] [Abstract][Full Text] [Related]
10. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
11. [Results with the use of the M-2 protocol in plasmacytoma].
Ho AD; Wittkamp S; Theml H; Keilholz U; Hunstein W
Dtsch Med Wochenschr; 1986 May; 111(22):858-61. PubMed ID: 3754811
[TBL] [Abstract][Full Text] [Related]
12. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
Herold M; Schulze A; Niederwieser D; Franke A; Fricke HJ; Richter P; Freund M; Ismer B; Dachselt K; Boewer C; Schirmer V; Weniger J; Pasold R; Winkelmann C; Klinkenstein C; Schulze M; Arzberger H; Bremer K; Hahnfeld S; Schwarzer A; Müller C; Müller C;
J Cancer Res Clin Oncol; 2006 Feb; 132(2):105-12. PubMed ID: 16088404
[TBL] [Abstract][Full Text] [Related]
13. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M
Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590
[No Abstract] [Full Text] [Related]
15. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B
J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
[TBL] [Abstract][Full Text] [Related]
16. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
[TBL] [Abstract][Full Text] [Related]
17. Waldenström's macroglobulinemia: long-term results with the M-2 protocol.
Case DC; Ervin TJ; Boyd MA; Redfield DL
Cancer Invest; 1991; 9(1):1-7. PubMed ID: 1901509
[TBL] [Abstract][Full Text] [Related]
18. Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis.
Hansen OP; Clausen NA; Drivsholm A; Laursen B
Scand J Haematol; 1985 Nov; 35(5):518-24. PubMed ID: 3911373
[TBL] [Abstract][Full Text] [Related]
19. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma.
Ezdinli EZ; Anderson JR; Melvin F; Glick JH; Davis TE; O'Connell MJ
J Clin Oncol; 1985 Jun; 3(6):769-75. PubMed ID: 3839262
[TBL] [Abstract][Full Text] [Related]
20. Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone.
Bowen DA; Call TG; Shanafelt TD; Kay NE; Schwager SM; Reinalda MS; Rabe KG; Slager SL; Zent CS
Leuk Lymphoma; 2010 Apr; 51(4):620-7. PubMed ID: 20302386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
